Sagimet Biosciences Files 8-K Report
Ticker: SGMT · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1400118
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Sagimet Biosciences filed an 8-K on Jan 2, 2025, mostly procedural stuff.
AI Summary
On January 2, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly known as 3-V Biosciences, Inc., is incorporated in Delaware and headquartered in San Mateo, California.
Why It Matters
This 8-K filing indicates Sagimet Biosciences Inc. is fulfilling its reporting obligations with the SEC, though the specific details of 'Other Events' are not elaborated in this excerpt.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or events.
Key Numbers
- 001-41742 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-5991472 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- 3-V Biosciences, Inc. (company) — Former Company Name
- January 2, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Mateo, California (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Sagimet Biosciences Inc. on January 2, 2025?
The provided text of the 8-K filing does not specify the details of the 'Other Events'.
What is the former name of Sagimet Biosciences Inc. and when did the name change occur?
The former name was 3-V Biosciences, Inc., and the date of the name change was May 21, 2007.
Where are Sagimet Biosciences Inc.'s principal executive offices located?
The principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
What is the company's SEC file number?
The SEC file number for Sagimet Biosciences Inc. is 001-41742.
What is the fiscal year end for Sagimet Biosciences Inc.?
The fiscal year end for Sagimet Biosciences Inc. is December 31.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-02 08:00:28
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2431774d1_8k.htm (8-K) — 26KB
- tm2431774d1_ex99-1.htm (EX-99.1) — 49KB
- tm2431774d1_ex99-1img001.jpg (GRAPHIC) — 128KB
- tm2431774d1_ex99-1img002.jpg (GRAPHIC) — 331KB
- tm2431774d1_ex99-1img003.jpg (GRAPHIC) — 160KB
- tm2431774d1_ex99-1img004.jpg (GRAPHIC) — 180KB
- tm2431774d1_ex99-1img005.jpg (GRAPHIC) — 140KB
- tm2431774d1_ex99-1img006.jpg (GRAPHIC) — 106KB
- tm2431774d1_ex99-1img007.jpg (GRAPHIC) — 133KB
- tm2431774d1_ex99-1img008.jpg (GRAPHIC) — 119KB
- tm2431774d1_ex99-1img009.jpg (GRAPHIC) — 132KB
- tm2431774d1_ex99-1img010.jpg (GRAPHIC) — 70KB
- tm2431774d1_ex99-1img011.jpg (GRAPHIC) — 139KB
- tm2431774d1_ex99-1img012.jpg (GRAPHIC) — 162KB
- tm2431774d1_ex99-1img013.jpg (GRAPHIC) — 107KB
- tm2431774d1_ex99-1img014.jpg (GRAPHIC) — 97KB
- tm2431774d1_ex99-1img015.jpg (GRAPHIC) — 127KB
- tm2431774d1_ex99-1img016.jpg (GRAPHIC) — 146KB
- tm2431774d1_ex99-1img017.jpg (GRAPHIC) — 105KB
- tm2431774d1_ex99-1img018.jpg (GRAPHIC) — 144KB
- tm2431774d1_ex99-1img019.jpg (GRAPHIC) — 108KB
- tm2431774d1_ex99-1img020.jpg (GRAPHIC) — 101KB
- tm2431774d1_ex99-1img021.jpg (GRAPHIC) — 115KB
- tm2431774d1_ex99-1img022.jpg (GRAPHIC) — 105KB
- tm2431774d1_ex99-1img023.jpg (GRAPHIC) — 145KB
- tm2431774d1_ex99-1img024.jpg (GRAPHIC) — 146KB
- tm2431774d1_ex99-1img025.jpg (GRAPHIC) — 164KB
- tm2431774d1_ex99-1img026.jpg (GRAPHIC) — 151KB
- tm2431774d1_ex99-1img027.jpg (GRAPHIC) — 163KB
- tm2431774d1_ex99-1img028.jpg (GRAPHIC) — 71KB
- tm2431774d1_ex99-1img029.jpg (GRAPHIC) — 81KB
- tm2431774d1_ex99-1img030.jpg (GRAPHIC) — 141KB
- tm2431774d1_ex99-1img031.jpg (GRAPHIC) — 170KB
- tm2431774d1_ex99-1img032.jpg (GRAPHIC) — 145KB
- tm2431774d1_ex99-1img033.jpg (GRAPHIC) — 144KB
- tm2431774d1_ex99-1img034.jpg (GRAPHIC) — 161KB
- tm2431774d1_ex99-1img035.jpg (GRAPHIC) — 147KB
- tm2431774d1_ex99-1img036.jpg (GRAPHIC) — 193KB
- 0001104659-25-000137.txt ( ) — 7121KB
- sgmt-20250102.xsd (EX-101.SCH) — 3KB
- sgmt-20250102_lab.xml (EX-101.LAB) — 33KB
- sgmt-20250102_pre.xml (EX-101.PRE) — 22KB
- tm2431774d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On January 2, 2025, Sagimet Biosciences Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated January 2, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: January 2, 2025 By: /s/ David Happel David Happel Chief Executive Officer